Article reading: https://www.hipdf.com/download-file?share_id=M6KhP2ZEpOduS01bbk1Mxw

Please provide an explanation of answers

Question 1 12.5 pts The objective of this trial was to Test a combination medication regimen of two approved therapies for smoking dependence compared with a monotherapy regimen. Test a new unapproved medication for the treatment of smoking dependence. Compare two approved medications for smoking dependence. Question 2 12.5 pts The reason(s) subjects did not participate in this trial included Subjects were pregnant and Subjects could not swallow pills. None of the choices O Subjects smoked 20 or more cigarettes a week Question 3 12.5 pts The study was blinded by the administration of Open-label varenicline and double-blind buproprion SR or placebo. The study was not blinded. Double-blind bupropion SR or placebo and double-blind varenicline or placebo. Open-label bupropion SR and double-blind varenicline or placebo.Question 4 12.5 pts The primary end point of the study was ____ ' Prolonged smoking abstinence rates at week 26. ' Prolonged smoking abstinence rates at week 26. ' The biochemically conrmed prolonged and 7-day point-prevalence smoking abstinence rates at week 12. ' A CO level of >8 ppm. Question 5 12.5 pts Exploratory analyses were performed to examine the effect of __________ on treatment effect. ' Sex and Baseline smoking rate ' Race 7 Sex ' Baseline smoking rate Question 6 12.5 pts Depressive symptoms were not reported more frequently with combination therapy than with monotherapy. ' True ' False Question 7 12.5 pts Among cigarette smokers, the combined use of varenicline and bupropion SR, compared with varenicline alone, resulted in an increase in prolonged smoking abstinence but not 7-day point-prevalence smoking abstinence ____ ' At 12 weeks. ' At 12 and 26 weeks. ' At 26 weeks. ' At 52 weeks. Question 8 12.5 pts Summary This study was conducted to evaluate the safety and efcacy of a combination therapy approach to smoking cessation treatment compared with a single approved agent. This randomized placebo-controlled trial enrolled 506 subjects who received at least one dose of study medication. 366 subjects completed 12 weeks of treatment, and 315 completed 52 weeks of treatment. The end points were analyzed using logistic regression. The combination treatment regimen resulted in an increase in prolonged smoking abstinence but not 7-day point prevalence smoking abstinence rate compared with varenicline alone at 12 and 26 weeks; neither outcome was signicantly different at 52 weeks. The 95% condence intervals for the odds ratios for 7-day point prevalence smoking cessation abstinence comparisons contained 1. Neither age nor sex was found to have a signicant effect on the primary endpoint variables. Baseline smoking rate (light vs. heavy) and level of nicotine dependence (low/moderate vs. high) were found to have signicant treatment effect interactions. Adjusted odds ratios for the primary end point variables for both baseline smoking and level of nicotine dependence were presented separately for these factors because of the interactions. Anxiety and depressive symptoms were reported more frequently with combination therapy than with monotherapy, both of which are associated with tobacco withdrawal. ' I have read and understand the summary ' l have NOT read the summary